alertmeipp
25 minutes ago
I still find it hard to believe that ENTA is trading at a $130 million market cap, with a negative enterprise value! All while it’s competing with major pharmaceutical companies in developing treatments for COVID, HBV, and RSV—and is even leading in certain areas. It's really odd.